US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
PT1523496E
(pt)
|
2002-07-18 |
2011-09-29 |
Merus B V |
Produção de misturas de anticorpos de forma recombinante
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
KR101922788B1
(ko)
|
2007-09-26 |
2018-11-27 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
EP2275443B1
(en)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
WO2010107109A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
KR101904065B1
(ko)
|
2009-06-26 |
2018-10-04 |
리제너론 파마슈티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
WO2011028753A1
(en)
*
|
2009-09-01 |
2011-03-10 |
Genentech, Inc. |
Enhanced protein purification through a modified protein a elution
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP6087054B2
(ja)
*
|
2009-12-25 |
2017-03-01 |
中外製薬株式会社 |
ポリペプチド多量体を精製するためのポリペプチドの改変方法
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
PL3095871T3
(pl)
|
2010-02-08 |
2019-10-31 |
Regeneron Pharma |
Mysz zawierająca wspólny łańcuch lekki
|
US20130045492A1
(en)
*
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
SG10201800757TA
(en)
*
|
2010-04-20 |
2018-02-27 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
CN103154255B
(zh)
|
2010-08-02 |
2016-04-06 |
瑞泽恩制药公司 |
制造包含vl结构域的结合蛋白的小鼠
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
WO2012058768A1
(en)
|
2010-11-05 |
2012-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
WO2012067176A1
(ja)
|
2010-11-17 |
2012-05-24 |
中外製薬株式会社 |
血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
CA2819530C
(en)
|
2010-11-30 |
2023-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
WO2012132067A1
(ja)
*
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
CA2827923C
(en)
*
|
2011-02-25 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc antibody
|
TWI588156B
(zh)
|
2011-03-28 |
2017-06-21 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
RU2641256C2
(ru)
*
|
2011-06-30 |
2018-01-16 |
Чугаи Сейяку Кабусики Кайся |
Гетеродимеризованный полипептид
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
HUE055276T2
(hu)
|
2011-08-05 |
2021-11-29 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
DK3216871T3
(da)
*
|
2011-10-17 |
2022-02-21 |
Regeneron Pharma |
Mus med indskrænket tung immunoglobulinkæde
|
EP3674320A3
(en)
|
2011-10-27 |
2020-08-12 |
Genmab A/S |
Production of heterodimeric proteins
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
SI2780368T1
(en)
|
2011-11-14 |
2018-04-30 |
Regeneron Pharmaceuticals, Inc. |
INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
|
EP3574897B1
(en)
|
2011-11-18 |
2022-01-05 |
Regeneron Pharmaceuticals, Inc. |
Extended release formulation comprising polymer protein microparticles for use in the vitreous of the eye for treating vascular eye disorders
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
AU2012355415B2
(en)
*
|
2011-12-20 |
2017-07-06 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
UY34652A
(es)
|
2012-03-02 |
2013-09-02 |
Regeneron Pharma |
Anticuerpos humanos frente a toxinas de clostridium difficile
|
IN2014DN08163A
(es)
|
2012-03-06 |
2015-05-01 |
Regeneron Pharma |
|
JP6273219B2
(ja)
|
2012-03-13 |
2018-01-31 |
ノビミューン エスアー |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
CN106318951A
(zh)
|
2012-03-16 |
2017-01-11 |
瑞泽恩制药公司 |
生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
|
NZ629077A
(en)
|
2012-03-16 |
2015-12-24 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
SI2883449T1
(en)
|
2012-03-16 |
2018-05-31 |
Regeneron Pharmaceuticals, Inc. |
Light-chain modified antibodies with histidine and genetically modified rodents for their production
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
JP6393255B2
(ja)
|
2012-04-20 |
2018-09-19 |
メルス ナムローゼ フェンノートシャップ |
ヘテロ二量体のIgG様分子を生産する方法、ヘテロ二量体のIgG様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
|
US20150065690A1
(en)
|
2012-04-27 |
2015-03-05 |
Bioatla, Llc |
Modified antibody regions and uses thereof
|
PT2858487T
(pt)
|
2012-06-12 |
2020-01-15 |
Regeneron Pharma |
Animais não humanos humanizados com locus de cadeias pesadas imunoglobulina restrito
|
WO2013187495A1
(ja)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
TWI717591B
(zh)
|
2012-08-24 |
2021-02-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
JOP20200236A1
(ar)
*
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
IN2015MN00139A
(es)
|
2012-09-25 |
2015-10-16 |
Glenmark Pharmaceuticals Sa |
|
WO2014051433A1
(en)
|
2012-09-27 |
2014-04-03 |
Merus B.V. |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
EP2905290B1
(en)
*
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
EP2914634B1
(en)
|
2012-11-02 |
2017-12-06 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
JP6506024B2
(ja)
|
2012-11-05 |
2019-04-24 |
全薬工業株式会社 |
抗体又は抗体組成物の製造方法
|
TWI745610B
(zh)
*
|
2012-11-14 |
2021-11-11 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
EP2925785A4
(en)
|
2012-11-28 |
2016-11-16 |
Zymeworks Inc |
MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
|
WO2014104165A1
(ja)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
KR20210096697A
(ko)
|
2013-01-10 |
2021-08-05 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
CA2897963A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
AU2014244020B2
(en)
|
2013-03-13 |
2020-06-04 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
EP2970437A1
(en)
|
2013-03-13 |
2016-01-20 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
ES2898620T3
(es)
|
2013-03-14 |
2022-03-08 |
Regeneron Pharma |
Anticuerpos humanos contra GREM 1
|
AU2014244286B2
(en)
|
2013-03-14 |
2018-11-08 |
Duke University |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
SG11201505901YA
(en)
*
|
2013-03-14 |
2015-08-28 |
Emd Millipore Corp |
Methods of increasing protein purity using protein a based chromatography
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
US11357866B2
(en)
*
|
2013-04-03 |
2022-06-14 |
The Administrators Of The Tulane Educational Fund |
Expression of HIV inhibitors by mesenchymal stem cells
|
TWI747803B
(zh)
|
2013-04-29 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
人類結合fcrn之經修飾抗體及使用方法
|
MX2015015060A
(es)
*
|
2013-04-29 |
2016-02-25 |
Hoffmann La Roche |
Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素a之抗體及其用途
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
WO2015033223A2
(en)
*
|
2013-09-03 |
2015-03-12 |
Novimmune S.A. |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
US9481729B2
(en)
*
|
2013-09-11 |
2016-11-01 |
The University Of Hong Kong |
Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
|
KR102150414B1
(ko)
|
2013-09-18 |
2020-09-02 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
|
KR102441231B1
(ko)
*
|
2013-09-27 |
2022-09-06 |
추가이 세이야쿠 가부시키가이샤 |
폴리펩티드 이종 다량체의 제조방법
|
WO2015063339A1
(en)
|
2013-11-04 |
2015-05-07 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
MA39061A1
(fr)
|
2013-11-20 |
2017-10-31 |
Regeneron Pharma |
Modulateurs d'aplnr et leurs utilisations
|
WO2015077891A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
JP2017029001A
(ja)
*
|
2013-12-19 |
2017-02-09 |
国立研究開発法人産業技術総合研究所 |
プロテインgの細胞膜外ドメインの新規な改変型タンパク質
|
MX2016008782A
(es)
|
2014-01-15 |
2016-09-08 |
Hoffmann La Roche |
Variantes de region fc con union mejorada de la proteina a.
|
KR20160107190A
(ko)
|
2014-01-15 |
2016-09-13 |
에프. 호프만-라 로슈 아게 |
변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
US20170058045A1
(en)
*
|
2014-02-21 |
2017-03-02 |
Regeneron Pharmaceuticals, Inc. |
Methods, compositions and kits for cell specific modulation of target antigens
|
WO2015130172A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibodies that bind egfr and erbb3
|
ES2826774T3
(es)
|
2014-02-28 |
2021-05-19 |
Merus Nv |
Anticuerpo que se une a ERBB-2 y ERBB-3
|
TWI701042B
(zh)
*
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
KR20210088756A
(ko)
|
2014-03-21 |
2021-07-14 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
BR112016021679A2
(pt)
|
2014-03-21 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
|
HUE048734T2
(hu)
|
2014-03-28 |
2020-08-28 |
Xencor Inc |
CD38-hoz és CD3-hoz kötõdõ bispecifikus ellenanyagok
|
PL3130606T3
(pl)
|
2014-04-07 |
2022-02-07 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciała dwuswoiste aktywujące układ odpornościowy
|
WO2015174439A1
(ja)
*
|
2014-05-13 |
2015-11-19 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
EA201692476A1
(ru)
|
2014-05-28 |
2017-07-31 |
Займворкс Инк. |
Модифицированные антигенсвязывающие полипептидные конструкции и их применение
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
WO2015184203A1
(en)
|
2014-05-29 |
2015-12-03 |
Macrogenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
AR101262A1
(es)
*
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
SG10201804931QA
(en)
|
2014-09-12 |
2018-07-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
EP3201227A4
(en)
|
2014-09-29 |
2018-04-18 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
RS59340B1
(sr)
*
|
2014-11-06 |
2019-10-31 |
Hoffmann La Roche |
Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
DK3221359T3
(da)
|
2014-11-17 |
2020-06-22 |
Regeneron Pharma |
Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3および腫瘍抗原に結合するヘテロ二量体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
MA41019A
(fr)
|
2014-11-26 |
2021-05-05 |
Xencor Inc |
Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
|
DK3029137T3
(en)
|
2014-12-06 |
2019-04-08 |
Gemoab Monoclonals Gmbh |
GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
|
TWI702229B
(zh)
|
2014-12-19 |
2020-08-21 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
US10221248B2
(en)
|
2014-12-22 |
2019-03-05 |
The Rockefeller University |
Anti-MERTK agonistic antibodies and uses thereof
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
WO2016149678A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
TWI804917B
(zh)
|
2015-03-27 |
2023-06-11 |
美商再生元醫藥公司 |
偵測生物污染物之組成物及方法
|
US10556952B2
(en)
|
2015-03-30 |
2020-02-11 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to Fc gamma receptors
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
AU2016249015B2
(en)
|
2015-04-15 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Methods of increasing strength and functionality with GDF8 inhibitors
|
MA56416A
(fr)
|
2015-05-12 |
2022-05-04 |
Regeneron Pharma |
Détermination de la pureté de protéines multimériques
|
RS60792B1
(sr)
|
2015-05-29 |
2020-10-30 |
Agenus Inc |
Anti-ctla-4 antitela i postupci za njihovu primenu
|
US11236150B2
(en)
|
2015-06-15 |
2022-02-01 |
Numab Therapeutics AG |
Hetero-dimeric multi-specific antibody format
|
WO2016205200A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cll-1 antibodies and methods of use
|
US10113003B2
(en)
|
2015-06-23 |
2018-10-30 |
Innate Pharma |
Multispecific NK engager proteins
|
EP3319994B1
(en)
|
2015-07-06 |
2024-02-07 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
US20180201693A1
(en)
|
2015-07-09 |
2018-07-19 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
EP3319993B1
(en)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
CN108026174B
(zh)
|
2015-07-10 |
2023-02-17 |
美勒斯公司 |
人cd3结合抗体
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EP3307321A4
(en)
*
|
2015-08-26 |
2019-04-17 |
Bison Therapeutics Inc. |
MULTISPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
RU2018116846A
(ru)
|
2015-10-08 |
2019-11-08 |
Займворкс Инк. |
Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
EP3365373B1
(en)
|
2015-10-23 |
2021-03-10 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
EP3378487B1
(en)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Cd3及びpsmaに結合するヘテロ二量体抗体
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
|
GB201602156D0
(en)
*
|
2016-02-05 |
2016-03-23 |
Jones Philip C And Boku University Of Natural Resources And Life Sciences |
Heterodimers and purification thereof
|
TW202214700A
(zh)
|
2016-03-14 |
2022-04-16 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
EP3433281A1
(en)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
AU2017253241A1
(en)
*
|
2016-04-20 |
2018-09-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
BR112018071285A2
(pt)
|
2016-04-20 |
2019-02-12 |
Regeneron Pharma |
célula, conjunto de vetores, vetor, sistema, e, método
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
WO2017194597A1
(en)
|
2016-05-11 |
2017-11-16 |
Ge Healthcare Bioprocess R&D Ab |
Separation matrix
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
US11708390B2
(en)
|
2016-05-11 |
2023-07-25 |
Cytiva Bioprocess R&D Ab |
Method of storing a separation matrix
|
ES2909833T3
(es)
|
2016-05-11 |
2022-05-10 |
Cytiva Bioprocess R & D Ab |
Método de limpieza y/o desinfección de una matriz de separación
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
SG11201809552SA
(en)
|
2016-05-20 |
2018-11-29 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide rnas
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
EP4257613A3
(en)
|
2016-06-14 |
2023-12-13 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
US10633434B2
(en)
|
2016-06-14 |
2020-04-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-C5 antibodies
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
IL265369B2
(en)
|
2016-09-23 |
2024-03-01 |
Regeneron Pharma |
Antibodies against (MUCIN 16) MUC16
|
US10772972B2
(en)
|
2016-09-23 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
|
EP3526256A1
(en)
|
2016-10-11 |
2019-08-21 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
PE20191033A1
(es)
|
2016-10-14 |
2019-08-05 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
US20190276549A1
(en)
|
2016-11-01 |
2019-09-12 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
AU2017361081A1
(en)
|
2016-11-15 |
2019-05-23 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
KR20230037664A
(ko)
|
2016-12-07 |
2023-03-16 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
EP3559032A1
(en)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
TWI781130B
(zh)
|
2017-01-03 |
2022-10-21 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素a毒素之人類抗體
|
RU2019128134A
(ru)
|
2017-02-07 |
2021-03-09 |
Дайити Санкио Компани, Лимитед |
Антитело против gprc5d и молекула, содержащая антитело
|
JP2020506208A
(ja)
|
2017-02-10 |
2020-02-27 |
ゲンマブ ビー.ブイ. |
ポリペプチドバリアントおよびそれらの使用
|
MA46814B2
(fr)
|
2017-02-10 |
2022-09-30 |
Regeneron Pharma |
Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
US10626169B2
(en)
|
2017-02-17 |
2020-04-21 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
JP7304288B2
(ja)
|
2017-02-17 |
2023-07-06 |
サノフイ |
ジストログリカンおよびラミニン2に対する特異性を有する多特異性結合性分子
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
CN110612309A
(zh)
|
2017-03-27 |
2019-12-24 |
细胞基因公司 |
用于降低免疫原性的方法和组合物
|
CN110914301A
(zh)
|
2017-03-31 |
2020-03-24 |
健玛保控股有限公司 |
双特异性抗cd37抗体,单克隆抗cd37抗体及其使用方法
|
EP3600413A1
(en)
|
2017-03-31 |
2020-02-05 |
Merus N.V. |
Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
CA3058477A1
(en)
|
2017-04-11 |
2018-10-18 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
ES2952961T3
(es)
|
2017-05-01 |
2023-11-07 |
Agenus Inc |
Anticuerpos anti-TIGIT y métodos de uso de los mismos
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
JP2020522267A
(ja)
|
2017-06-05 |
2020-07-30 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
|
WO2018224951A2
(en)
*
|
2017-06-05 |
2018-12-13 |
Janssen Biotech, Inc. |
Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
|
EP3635005A1
(en)
|
2017-06-07 |
2020-04-15 |
Genmab B.V. |
Therapeutic antibodies based on mutated igg hexamers
|
WO2018226861A1
(en)
|
2017-06-07 |
2018-12-13 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
CA3066947A1
(en)
|
2017-06-27 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
|
SG11201911886PA
(en)
|
2017-06-27 |
2020-01-30 |
Regeneron Pharma |
Non-human animals comprising a humanized asgr1 locus
|
MA49512A
(fr)
|
2017-06-28 |
2020-05-06 |
Regeneron Pharma |
Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
|
WO2019005756A1
(en)
|
2017-06-28 |
2019-01-03 |
The Rockefeller University |
CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
KR20200024304A
(ko)
*
|
2017-07-06 |
2020-03-06 |
니토 보세키 가부시기가이샤 |
항인간 IgG4 모노클로날 항체, 및 그 항체를 이용한 인간 IgG4 측정 시약
|
EP3649144A4
(en)
|
2017-07-06 |
2021-07-21 |
Regeneron Pharmaceuticals, Inc. |
CELL CULTURE METHOD FOR PRODUCING A GLYCOPROTEIN
|
TW201919582A
(zh)
|
2017-07-24 |
2019-06-01 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
EP3661555A4
(en)
*
|
2017-08-01 |
2021-07-14 |
Ab Studio Inc. |
SPECIFIC ANTIBODIES AND USES THEREOF
|
TW202246308A
(zh)
|
2017-08-03 |
2022-12-01 |
美商安進公司 |
介白素-21突變蛋白及治療方法
|
TW201910354A
(zh)
|
2017-08-09 |
2019-03-16 |
荷蘭商美勒斯公司 |
結合表皮生長因子受體(EGFR)及cMET的抗體
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
KR20200039778A
(ko)
|
2017-08-22 |
2020-04-16 |
사나바이오, 엘엘씨 |
가용성 인터페론 수용체 및 그의 용도
|
IL272512B
(en)
|
2017-09-08 |
2022-07-01 |
Amgen Inc |
kras g12c inhibitors and methods of using them
|
US20200277373A1
(en)
*
|
2017-09-14 |
2020-09-03 |
Denali Therapeutics Inc. |
Anti-trem2 antibodies and methods of use thereof
|
CA3071712C
(en)
|
2017-09-29 |
2023-02-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus and methods of use
|
JP2021500865A
(ja)
|
2017-09-29 |
2021-01-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
スタフィロコッカス(Staphsylococcus)標的抗原および補体成分に結合する二重特異性抗原結合分子ならびにその使用
|
US20200317795A1
(en)
|
2017-10-04 |
2020-10-08 |
Amgen Inc. |
Transthyretin immunoglobulin fusions
|
CA3078157A1
(en)
|
2017-10-20 |
2019-04-25 |
F.Hoffmann-La Roche Ag |
Method for generating multispecific antibodies from monospecific antibodies
|
CA3078676A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
CA3081152A1
(en)
|
2017-11-02 |
2019-05-09 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding alk-1 and bmpr-2
|
CN111741757B
(zh)
*
|
2017-11-03 |
2023-12-19 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
CA3076377A1
(en)
|
2017-11-30 |
2019-06-06 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized trkb locus
|
JP2021506241A
(ja)
|
2017-12-13 |
2021-02-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗c5抗体組み合わせ物およびその使用
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
AU2018387829A1
(en)
|
2017-12-22 |
2020-05-07 |
Argenx Bvba |
Bispecific antigen binding construct
|
CA3084059A1
(en)
|
2017-12-22 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
PE20211270A1
(es)
|
2018-01-12 |
2021-07-19 |
Amgen Inc |
Anticuerpos anti-pd-1 y metodos de tratamiento
|
MA51666A
(fr)
|
2018-01-24 |
2020-12-02 |
Genmab Bv |
Variants polypeptidiques et leurs utilisations
|
WO2019147867A1
(en)
|
2018-01-26 |
2019-08-01 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to influenza hemagglutinin
|
EA202091689A1
(ru)
|
2018-01-31 |
2020-10-22 |
Ридженерон Фармасьютикалз, Инк. |
Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство
|
TWI825066B
(zh)
|
2018-02-01 |
2023-12-11 |
美商再生元醫藥公司 |
治療性單株抗體之品質屬性的定量及模型化
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
WO2019168774A1
(en)
|
2018-02-28 |
2019-09-06 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
JP2021515003A
(ja)
|
2018-03-01 |
2021-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
体組成を変更するための方法
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
BR112020015291B1
(pt)
|
2018-03-19 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc |
Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
|
US20190292263A1
(en)
|
2018-03-24 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
US20210246224A1
(en)
|
2018-04-30 |
2021-08-12 |
Regeneron Pharmaceuticals, Inc. |
Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
|
US20210238296A1
(en)
|
2018-05-03 |
2021-08-05 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
JP2021525087A
(ja)
|
2018-06-01 |
2021-09-24 |
コンピュジェン リミテッド |
抗pvrig/抗tigit二重特異性抗体および使用方法
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
EP3810270A1
(en)
|
2018-06-19 |
2021-04-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-factor xii/xiia antibodies and uses thereof
|
TW202005985A
(zh)
|
2018-06-21 |
2020-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
|
WO2019243626A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab A/S |
Method for producing a controlled mixture of two or more different antibodies
|
WO2019243636A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
EP3816291A4
(en)
|
2018-06-26 |
2022-03-16 |
Kyowa Kirin Co., Ltd. |
CHONDROITIN SULFATE PROTEOGLYCAN-5 BINDING ANTIBODIES
|
KR20210027295A
(ko)
|
2018-06-26 |
2021-03-10 |
쿄와 기린 가부시키가이샤 |
세포 부착 분자3에 결합하는 항체
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
EA202190228A1
(ru)
*
|
2018-07-10 |
2021-04-14 |
Ридженерон Фармасьютикалз, Инк. |
Модификация связывающих молекул для минимизации уже существующих взаимодействий
|
TW202012926A
(zh)
|
2018-07-13 |
2020-04-01 |
美商再生元醫藥公司 |
醣基化肽之偵測及定量
|
JP2021524276A
(ja)
|
2018-07-13 |
2021-09-13 |
ゲンマブ エー/エス |
Cd38抗体のバリアントおよびその使用
|
JP2021526845A
(ja)
|
2018-07-13 |
2021-10-11 |
ゲンマブ エー/エス |
Cd38抗体を使用したトロゴサイトーシスを介した治療
|
WO2020018820A1
(en)
|
2018-07-19 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
|
CA3105891A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
CN112639471B
(zh)
|
2018-08-13 |
2024-04-09 |
瑞泽恩制药公司 |
在模拟体内条件下的治疗性蛋白质选择
|
BR112021002724A2
(pt)
|
2018-08-17 |
2021-07-20 |
Regeneron Pharmaceuticals, Inc. |
método para quantificar uma quantidade de um anticorpo heterodimérico, e, sistema de cromatografia
|
EP3837553A1
(en)
|
2018-08-17 |
2021-06-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for de novo protein sequencing
|
US11578127B2
(en)
|
2018-08-23 |
2023-02-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof
|
MX2021002279A
(es)
|
2018-08-27 |
2021-05-27 |
Regeneron Pharma |
Uso de espectroscopia raman en la purificacion corriente abajo.
|
KR20210053816A
(ko)
|
2018-08-30 |
2021-05-12 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질 복합체를 특성화하기 위한 방법
|
CN112771077A
(zh)
|
2018-08-31 |
2021-05-07 |
瑞泽恩制药公司 |
针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
AU2019355971A1
(en)
|
2018-10-03 |
2021-05-06 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
AU2019354105A1
(en)
|
2018-10-04 |
2021-04-29 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
|
WO2020076977A2
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
JP2022504802A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
5t4シングルドメイン抗体およびその治療組成物
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
US20230124851A1
(en)
|
2018-10-11 |
2023-04-20 |
Inhibrx, lnc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
JP7439076B2
(ja)
|
2018-10-23 |
2024-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗npr1抗体およびその使用
|
KR20210082183A
(ko)
|
2018-10-25 |
2021-07-02 |
리제너론 파아마슈티컬스, 인크. |
바이러스 캡시드 단백질 조성물의 분석 방법
|
MX2021004732A
(es)
*
|
2018-10-26 |
2021-06-04 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd38.
|
SG11202103628PA
(en)
|
2018-10-31 |
2021-05-28 |
Regeneron Pharma |
Method and system of identifying and quantifying a protein
|
EP3877409A1
(en)
|
2018-11-06 |
2021-09-15 |
Genmab A/S |
Antibody formulation
|
US20220332800A1
(en)
|
2018-11-20 |
2022-10-20 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
CN112867732A
(zh)
|
2018-11-21 |
2021-05-28 |
瑞泽恩制药公司 |
抗葡萄球菌抗体和其用途
|
US11249089B2
(en)
|
2018-12-12 |
2022-02-15 |
Regeneron Pharmaceuticals, Inc. |
System and method of analysis of a protein using liquid chromatography-mass spectrometry
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
US11782023B2
(en)
|
2018-12-19 |
2023-10-10 |
Regeneron Pharmaceuticals, Inc. |
Ce-western applications for antibody development
|
HUE057634T2
(hu)
|
2018-12-21 |
2022-05-28 |
Kymab Ltd |
FIXAXFX bispecifikus ellenanyag közös könnyûlánccal
|
EP3902825A1
(en)
|
2018-12-24 |
2021-11-03 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
HUE061783T2
(hu)
|
2019-01-16 |
2023-08-28 |
Regeneron Pharma |
Módszerek diszulfidkötések jellemzésére
|
CN113646638A
(zh)
|
2019-01-31 |
2021-11-12 |
瑞泽恩制药公司 |
抗体电荷异质性的原生微流体ce-ms分析
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
GB2599229A
(en)
|
2019-02-21 |
2022-03-30 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
WO2020172596A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and thereof
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
MX2021010390A
(es)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a enpp3 y cd3.
|
MX2021011956A
(es)
|
2019-04-03 |
2021-12-15 |
Regeneron Pharma |
Metodos y composiciones para la insercion de secuencias codificantes de anticuerpos en un locus de puerto seguro.
|
CN117178959A
(zh)
|
2019-04-04 |
2023-12-08 |
瑞泽恩制药公司 |
包括人源化凝血因子12基因座的非人动物
|
MA55615A
(fr)
|
2019-04-10 |
2022-02-16 |
Regeneron Pharma |
Anticorps humains qui se lient au ret et leurs procédés d'utilisation
|
MA55881A
(fr)
|
2019-05-09 |
2022-03-16 |
Genmab Bv |
Schémas posologiques pour une combinaison d'anticorps anti-dr5 destinés à être utilisés dans le traitement du cancer
|
JP2022532795A
(ja)
|
2019-05-21 |
2022-07-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ホスト細胞タンパク質の同定および定量方法
|
JP2022534867A
(ja)
|
2019-06-04 |
2022-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ベータスリップ変異を有するヒト化ttr遺伝子座を含む非ヒト動物と使用方法
|
CA3136478A1
(en)
|
2019-06-05 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
CN113966343A
(zh)
|
2019-06-11 |
2022-01-21 |
瑞泽恩制药公司 |
结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
|
BR112021024417A2
(pt)
|
2019-06-13 |
2022-01-18 |
Regeneron Pharma |
Métodos para remoção de componentes indesejados durante processos cromatográficos de múltiplos estágios
|
US20200399372A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
US20200399371A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
|
WO2021007150A1
(en)
|
2019-07-08 |
2021-01-14 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
GB201910900D0
(en)
*
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
MX2022001682A
(es)
|
2019-08-08 |
2022-05-13 |
Regeneron Pharma |
Nuevos formatos de moleculas de union a antigenos.
|
WO2021030680A1
(en)
|
2019-08-15 |
2021-02-18 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
AU2020328049A1
(en)
|
2019-08-15 |
2022-02-17 |
Janssen Biotech, Inc. |
Materials and methods for improved single chain variable fragments
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
EP4051707A1
(en)
|
2019-10-28 |
2022-09-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-hemagglutinin antibodies and methods of use thereof
|
TW202134277A
(zh)
|
2019-11-05 |
2021-09-16 |
美商再生元醫藥公司 |
N—端scFv多特異性結合分子
|
JP2023500701A
(ja)
|
2019-11-06 |
2023-01-10 |
ジェンマブ ビー.ブイ. |
抗体変種の組み合わせおよびその使用
|
AU2020394428A1
(en)
|
2019-11-25 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
WO2021113297A1
(en)
|
2019-12-02 |
2021-06-10 |
Regeneron Pharmaceuticals, Inc. |
Peptide-mhc ii protein constructs and uses thereof
|
MY190624A
(en)
|
2019-12-06 |
2022-04-27 |
Regeneron Pharma |
Anti-vegf protein compositions and methods for producing the same
|
US11919965B2
(en)
|
2019-12-06 |
2024-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
|
JP2023506750A
(ja)
|
2019-12-11 |
2023-02-20 |
シラグ・ゲーエムベーハー・インターナショナル |
Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用
|
AU2020407233A1
(en)
|
2019-12-20 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Novel IL2 agonists and methods of use thereof
|
AU2020414489A1
(en)
|
2019-12-26 |
2022-07-14 |
Abl Bio Inc. |
Method for purifying biologically active peptide by using protein a affinity chromatography
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
US20210223259A1
(en)
|
2020-01-08 |
2021-07-22 |
Regeneron Pharmaceuticals, Inc. |
Use of Amino Acids to Enhance Signal in Mass Spectral Analyses
|
EP4090366A1
(en)
|
2020-01-16 |
2022-11-23 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
MX2022008973A
(es)
|
2020-01-21 |
2022-08-11 |
Regeneron Pharma |
Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
|
WO2021154764A1
(en)
|
2020-01-27 |
2021-08-05 |
Regeneron Pharmaceuticals, Inc. |
Tandem mass tag multiplexed quantitation of post-translational modifications of proteins
|
CN115175559A
(zh)
|
2020-01-28 |
2022-10-11 |
瑞泽恩制药公司 |
包含人源化pnpla3基因座的非人动物及其使用方法
|
US20230348600A1
(en)
|
2020-01-29 |
2023-11-02 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
AU2021214764A1
(en)
|
2020-01-30 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Platform for native liquid chromatography-mass spectrometry
|
US11371971B2
(en)
|
2020-01-31 |
2022-06-28 |
Regeneron Pharmaceuticals, Inc. |
High confidence compound identification by liquid chromatography-mass spectrometry
|
EP4099821A1
(en)
|
2020-02-07 |
2022-12-14 |
Regeneron Pharmaceuticals, Inc. |
<smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
|
AU2021218675A1
(en)
|
2020-02-11 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-ACVR1 antibodies and uses thereof
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
CA3173162A1
(en)
|
2020-03-25 |
2021-09-30 |
Eli Lilly And Company |
Multispecific binding proteins and methods of developing the same
|
AU2021246385A1
(en)
|
2020-03-30 |
2022-12-08 |
Daiichi Sankyo Company, Limited |
Bispecific antibody
|
US11885779B2
(en)
|
2020-04-14 |
2024-01-30 |
Regeneron Pharmaceuticals, Inc. |
Ultraviolet monitoring of chromatography performance by orthogonal partial least squares
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
WO2021228904A1
(en)
|
2020-05-11 |
2021-11-18 |
Academisch Medisch Centrum |
Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof
|
IL298007A
(en)
|
2020-05-12 |
2023-01-01 |
Regeneron Pharma |
Novel il10 agonists and methods of using them
|
CA3172471A1
(en)
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-glp1r antagonist antibodies and methods of use thereof
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
WO2021263146A2
(en)
|
2020-06-26 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ace2 locus
|
JP2023534726A
(ja)
|
2020-07-23 |
2023-08-10 |
ジェンマブ ビー.ブイ. |
多発性骨髄腫の治療に使用するための抗dr5抗体と免疫調節イミド薬との併用
|
KR20230048439A
(ko)
|
2020-08-18 |
2023-04-11 |
세파론 엘엘씨 |
항-par-2 항체 및 이의 사용 방법
|
MX2023001962A
(es)
|
2020-08-19 |
2023-04-26 |
Xencor Inc |
Composiciones anti-cd28.
|
US20220056119A1
(en)
|
2020-08-20 |
2022-02-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists
|
AU2021333779A1
(en)
|
2020-08-26 |
2023-04-13 |
Marengo Therapeutics, Inc. |
Methods of detecting TRBC1 or TRBC2
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
WO2022046922A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
KR20230058094A
(ko)
|
2020-08-31 |
2023-05-02 |
리제너론 파아마슈티컬스, 인크. |
세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
|
US20220090060A1
(en)
|
2020-09-11 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
IL301037A
(en)
|
2020-09-18 |
2023-05-01 |
Regeneron Pharma |
Antigen binding molecules that bind CD38 and/or CD28 and uses thereof
|
US20230365714A1
(en)
|
2020-10-02 |
2023-11-16 |
Genmab A/S |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
WO2022079199A1
(en)
|
2020-10-15 |
2022-04-21 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
MX2023004434A
(es)
|
2020-10-22 |
2023-05-08 |
Regeneron Pharma |
Anticuerpos anti-fgfr2 y metodos para usarlos.
|
US20240010748A1
(en)
|
2020-11-10 |
2024-01-11 |
Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. |
Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
|
TW202237070A
(zh)
|
2020-11-25 |
2022-10-01 |
美商再生元醫藥公司 |
使用非水性膜乳化之持續釋放調配物
|
CN114539416A
(zh)
*
|
2020-11-26 |
2022-05-27 |
盛禾(中国)生物制药有限公司 |
一种双特异性抗体的层析纯化工艺
|
EP4262757A1
(en)
|
2020-12-17 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
IL303542A
(en)
|
2020-12-18 |
2023-08-01 |
Regeneron Pharma |
Immunoglobulin proteins that bind to NPR1 agonists
|
WO2022133262A1
(en)
|
2020-12-20 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for identification of scrambled disulfides in biomolecules
|
AU2022206475A1
(en)
*
|
2021-01-11 |
2023-08-17 |
Adimab, Llc |
Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
|
WO2022159432A1
(en)
|
2021-01-20 |
2022-07-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving protein titer in cell culture
|
WO2022165039A1
(en)
|
2021-01-28 |
2022-08-04 |
Talem Therapeutics Llc |
Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
|
CN116963774A
(zh)
|
2021-01-28 |
2023-10-27 |
瑞泽恩制药公司 |
用于治疗细胞因子释放综合征的组合物和方法
|
EP4289866A2
(en)
|
2021-02-04 |
2023-12-13 |
Genuv Inc. |
Anti-pd-1 antibody and use thereof
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
TW202246325A
(zh)
|
2021-03-03 |
2022-12-01 |
美商再生元醫藥公司 |
用於定量及修飾蛋白質黏度之系統及方法
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
CN117321087A
(zh)
|
2021-03-26 |
2023-12-29 |
先天制药公司 |
包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
|
IL305818A
(en)
|
2021-03-29 |
2023-11-01 |
Daiichi Sankyo Co Ltd |
Multispecific stable compound and its use
|
AR125255A1
(es)
|
2021-04-02 |
2023-06-28 |
Regeneron Pharma |
Métodos de predicción y modulación de la glicación de una proteína
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
EP4320147A2
(en)
|
2021-04-08 |
2024-02-14 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
WO2022232083A1
(en)
|
2021-04-27 |
2022-11-03 |
Amgen Inc. |
Modulating product quality of asymmetric multispecific antibodies through the use of temperature
|
EP4334353A1
(en)
|
2021-05-04 |
2024-03-13 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
CA3218786A1
(en)
|
2021-05-25 |
2022-12-01 |
Lifei HOU |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
EP4352098A1
(en)
|
2021-06-09 |
2024-04-17 |
Innate Pharma |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
KR20240019786A
(ko)
|
2021-06-09 |
2024-02-14 |
이나뜨 파르마 에스.에이. |
Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
AU2022314734A1
(en)
|
2021-07-19 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
TW202322850A
(zh)
*
|
2021-08-05 |
2023-06-16 |
美商美國禮來大藥廠 |
抗體最佳化
|
TW202322846A
(zh)
|
2021-08-16 |
2023-06-16 |
美商再生元醫藥公司 |
新穎的il27受體促效劑及其使用方法
|
WO2023028612A2
(en)
|
2021-08-27 |
2023-03-02 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
WO2023031473A1
(en)
|
2021-09-06 |
2023-03-09 |
Genmab B.V. |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Fc蛋白之高通量及基於質譜之方法
|
WO2023081847A1
(en)
|
2021-11-04 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a modified cacng1 locus
|
TW202334223A
(zh)
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Cd20-pd1結合分子及其使用方法
|
WO2023097030A1
(en)
|
2021-11-24 |
2023-06-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
|
US20230250170A1
(en)
|
2021-12-06 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
US20230312718A1
(en)
|
2022-01-07 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc |
Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
|
TW202337900A
(zh)
|
2022-01-12 |
2023-10-01 |
美商再生元醫藥公司 |
改良使用親和層析的異二聚蛋白質自雜質之解析的方法
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
US20230257432A1
(en)
|
2022-02-11 |
2023-08-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
US20230265218A1
(en)
|
2022-02-23 |
2023-08-24 |
Xencor, Inc. |
Anti-cd28 x anti-psma antibodies
|
WO2023164627A1
(en)
|
2022-02-24 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-msln antibodies
|
WO2023164640A1
(en)
|
2022-02-24 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
WO2023177772A1
(en)
|
2022-03-17 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
WO2023201226A1
(en)
|
2022-04-11 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023224912A1
(en)
|
2022-05-16 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
WO2023230594A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024020199A1
(en)
|
2022-07-21 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Native microfluidic ce-ms analysis of antibody charge heterogeneity
|
WO2024026470A2
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
WO2024026488A2
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a modified transferrin receptor locus
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024030453A1
(en)
|
2022-08-02 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
WO2024073679A1
(en)
|
2022-09-29 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|